The "African Trypanosomiasis (Infectious Disease) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

African Trypanosomiasis - Drugs In Development, 2021, provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape.

African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 7 and 3 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.

African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

Key Topics Covered:

Introduction

African Trypanosomiasis - Overview

• African Trypanosomiasis - Therapeutics Development

Pipeline Overview

• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes

African Trypanosomiasis - Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

African Trypanosomiasis - Companies Involved in Therapeutics Development

• Cesa Alliance SA
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Incuron LLC
• MediSynergics LLC
• Novartis AG
• Paxmedica Inc
• Pfizer Inc
• Sanofi
• Scynexis Inc
• Synstar Japan Co Ltd

African Trypanosomiasis - Drug Profiles

• acoziborole
• AP-3
• CBL-0137
• DDD-100097
• fexinidazole
• GNF-6702
• MDL-73811
• melarsoprol hydroxypropylbetadex
• MS-08
• PAX-101
• Peptides for Sleeping Sickness
• SCYX-1330682
• SCYX-1608210
• Small Molecule for African Trypanosomiasis and Chagas Disease
• Small Molecules for Infectious Diseases
• Small Molecules for Protozoal Infections
• Small Molecules for Sleeping Sickness
• Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis
• Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis
• Small Molecules to Inhibit Rhodesain for African Trypanosomiasis
• Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis

African Trypanosomiasis - Dormant Projects

African Trypanosomiasis - Discontinued Products

African Trypanosomiasis - Product Development Milestones

Featured News & Press Releases

• Feb 02, 2021: PaxMedica receives FDA orphan drug designation for use of PAX-101 (IV suramin) in a rare tropical disease
• Nov 16, 2018: Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
• Nov 16, 2018: CHMP recommends first oral-only treatment for sleeping sickness
• Jan 31, 2018: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/se6h7v

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005368/en/